Natasha Kc, L W Preston Church, Pouria Riyahi, Sumana Chakravarty, Robert A Seder, Judith E Epstein, Kirsten E Lyke, Benjamin Mordmüller, Peter G Kremsner, Mahamadou S Sissoko, Sarah Healy, Patrick E Duffy, Said A Jongo, Vicente Urbano Nsue Ndong Nchama, Salim Abdulla, Maxmillian Mpina, Sodiomon B Sirima, Matthew B Laurens, Laura C Steinhardt, Martina Oneko, MingLin Li, Tooba Murshedkar, Peter F Billingsley, B Kim Lee Sim, Thomas L Richie, Stephen L Hoffman
Background: While prior research has shown differences in the risk of malaria infection and sickness between males and females, little is known about sex differences in vaccine-induced immunity to malaria. Identifying such differences could elucidate important aspects of malaria biology and facilitate development of improved approaches to malaria vaccination. Methods: Using a standardized enzyme-linked immunosorbent assay, IgG antibodies to the major surface protein on Plasmodium falciparum (Pf) sporozoites (SPZ), the Pf circumsporozoite protein (PfCSP), were measured before and two weeks after administration of a PfSPZ-based malaria vaccine (PfSPZ Vaccine) to 5-month to 61-year-olds in 11 clinical trials in Germany, the US and five countries in Africa, to determine if there were differences in vaccine elicited antibody response between males and females and if these differences were associated with differential protection against naturally transmitted Pf malaria (Africa) or controlled human malaria infection (Germany, the US and Africa)...
2022: Frontiers in Immunology